## **Anthony Ades**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1351752/publications.pdf

Version: 2024-02-01

73 papers 9,221 citations

126708 33 h-index 71 g-index

74 all docs

74 docs citations

times ranked

74

10284 citing authors

#	Article	IF	CITATIONS
1	Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment. Clinical Infectious Diseases, 2023, 76, 913-991.	2.9	9
2	Overall Vertical Transmission of Hepatitis C Virus, Transmission Net of Clearance, and Timing of Transmission. Clinical Infectious Diseases, 2023, 76, 905-912.	2.9	9
3	A nonâ€parametric approach for jointly combining evidence on progression free and overall survival time in network metaâ€analysis. Research Synthesis Methods, 2022, 13, 573-584.	4.2	2
4	Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies. Lancet Infectious Diseases, The, 2021, 21, 537-545.	4.6	38
5	Target estimands for efficient decision making: Response to comments on "Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study― Statistics in Medicine, 2021, 40, 2759-2763.	0.8	10
6	Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers. Journal of Infection, 2021, 82, 151-161.	1.7	7
7	Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study. EBioMedicine, 2021, 68, 103414.	2.7	17
8	Joint synthesis of conditionally related multiple outcomes makes better use of data than separate metaâ€analyses. Research Synthesis Methods, 2020, 11, 496-506.	4.2	3
9	Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study. Statistics in Medicine, 2020, 39, 4885-4911.	0.8	40
10	Estimating the prevalence of problem drug use from drugâ€related mortality data. Addiction, 2020, 115, 2393-2404.	1.7	20
11	Equivalence of entropy balancing and the method of moments for matchingâ€adjusted indirect comparison. Research Synthesis Methods, 2020, 11, 568-572.	4.2	14
12	Researching Zika in pregnancy: lessons for global preparedness. Lancet Infectious Diseases, The, 2020, 20, e61-e68.	4.6	15
13	Zika virus infection in pregnancy: a protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia. BMJ Open, 2020, 10, e035307.	0.8	10
14	Quantifying how diagnostic test accuracy depends on threshold in a metaâ€analysis. Statistics in Medicine, 2019, 38, 4789-4803.	0.8	24
15	Response to White and Lewis: Letter to editor in response to Has <i>Chlamydia trachomatis</i> prevalence in young women in England, Scotland and Wales changed? Evidence from national probability surveys. <i>Epidemiology and Infection. 2019</i>	1.0	O
16	The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. Lancet Psychiatry,the, 2019, 6, 903-914.	3.7	78
17	Population Adjustment Methods for Indirect Comparisons: A Review of National Institute for Health and Care Excellence Technology Appraisals. International Journal of Technology Assessment in Health Care, 2019, 35, 221-228.	0.2	45
18	Has <i>Chlamydia trachomatis</i> prevalence in young women in England, Scotland and Wales changed? Evidence from national probability surveys. Epidemiology and Infection, 2019, 147, e107.	1.0	4

#	Article	IF	Citations
19	Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT. Programme Grants for Applied Research, 2019, 7, 1-108.	0.4	6
20	Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. Medical Decision Making, 2018, 38, 200-211.	1.2	196
21	Use of a random effects metaâ€analysis in the design and analysis of a new clinical trial. Statistics in Medicine, 2018, 37, 4665-4679.	0.8	12
22	Extrapolation of Survival Curves from Cancer Trials Using External Information. Medical Decision Making, 2017, 37, 353-366.	1.2	48
23	Pelvic inflammatory disease and salpingitis: incidence of primary and repeat episodes in England. Epidemiology and Infection, 2017, 145, 208-215.	1.0	15
24	A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial. Trials, 2017, 18, 496.	0.7	15
25	Risk of reproductive complications following chlamydia testing. Lancet Infectious Diseases, The, 2016, 16, 1223-1224.	4.6	2
26	Proportion of Pelvic Inflammatory Disease Cases Caused by <i>Chlamydia trachomatis </i> Picture From Different Methods. Journal of Infectious Diseases, 2016, 214, 617-624.	1.9	40
27	A threshold analysis assessed the credibility of conclusions from network meta-analysis. Journal of Clinical Epidemiology, 2016, 80, 68-76.	2.4	20
28	Automated generation of nodeâ€splitting models for assessment of inconsistency in network metaâ€analysis. Research Synthesis Methods, 2016, 7, 80-93.	4.2	372
29	Problem drug use prevalence estimation revisited: heterogeneity in capture–recapture and the role of external evidence. Addiction, 2016, 111, 438-447.	1.7	24
30	Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetesâ€"Network meta-analysis of randomized trials. Journal of Diabetes and Its Complications, 2016, 30, 1192-1200.	1.2	31
31	The relative responsiveness of test instruments can be estimated using a meta-analytic approach: an illustration with treatments for depression. Journal of Clinical Epidemiology, 2016, 77, 68-77.	2.4	14
32	Absolute or relative effects? Armâ€based synthesis of trial data. Research Synthesis Methods, 2016, 7, 23-28.	4.2	74
33	The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. Health Technology Assessment, 2016, 20, 1-250.	1.3	358
34	Minimal clinically important difference on the Beck Depression Inventory - II according to the patient's perspective. Psychological Medicine, 2015, 45, 3269-3279.	2.7	202
35	Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy, 2015, 2, 113-125.	1.1	10
36	The Cost Effectiveness of Psychological and Pharmacological Interventions for Social Anxiety Disorder: A Model-Based Economic Analysis. PLoS ONE, 2015, 10, e0140704.	1.1	21

#	Article	IF	CITATIONS
37	Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment. Medical Decision Making, 2015, 35, 859-871.	1.2	44
38	Simultaneous synthesis of treatment effects and mapping to a common scale: an alternative to standardisation. Research Synthesis Methods, 2015, 6, 96-107.	4.2	18
39	Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses. Medical Decision Making, 2015, 35, 608-621.	1.2	16
40	Symptom lead times in lung and colorectal cancers: what are the benefits of symptom-based approaches to early diagnosis?. British Journal of Cancer, 2015, 112, 271-277.	2.9	43
41	Heightened risk of false positives in a network meta-analysis of social anxiety–Author's reply. Lancet Psychiatry,the, 2015, 2, 293-294.	3.7	0
42	No evidence of industry sponsorship bias in statin trials. BMJ, The, 2014, 349, g6579-g6579.	3.0	6
43	Incidence of <i>Chlamydia trachomatis</i> infection in women in England: two methods of estimation. Epidemiology and Infection, 2014, 142, 562-576.	1.0	10
44	Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2014, 1, 368-376.	3.7	484
45	Strategies for Efficient Computation of the Expected Value of Partial Perfect Information. Medical Decision Making, 2014, 34, 327-342.	1.2	32
46	Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ, The, 2014, 349, g5741-g5741.	3.0	55
47	Symptom lead time distribution in lung cancer: natural history and prospects for early diagnosis. International Journal of Epidemiology, 2014, 43, 1865-1873.	0.9	42
48	Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. Critical Care, 2014, 18, 649.	2.5	24
49	Expected Value of Sample Information for Multi-Arm Cluster Randomized Trials with Binary Outcomes. Medical Decision Making, 2014, 34, 352-365.	1.2	20
50	Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part B: Placing back-calculations in a formal statistical framework. Science of the Total Environment, 2014, 487, 642-650.	3.9	48
51	Simultaneous Multioutcome Synthesis and Mapping of Treatment Effects to a Common Scale. Value in Health, 2014, 17, 280-287.	0.1	18
52	Which Health-Related Quality-of-Life Outcome When Planning Randomized Trials: Disease-Specific or Generic, or Both? A Common Factor Model. Value in Health, 2013, 16, 185-194.	0.1	13
53	Evidence Synthesis for Decision Making 2. Medical Decision Making, 2013, 33, 607-617.	1.2	899
54	Evidence Synthesis for Decision Making 4. Medical Decision Making, 2013, 33, 641-656.	1.2	513

#	Article	IF	Citations
55	Evidence Synthesis for Decision Making 5. Medical Decision Making, 2013, 33, 657-670.	1.2	74
56	Evidence Synthesis for Decision Making 7. Medical Decision Making, 2013, 33, 679-691.	1.2	79
57	Evidence Synthesis for Decision Making 6. Medical Decision Making, 2013, 33, 671-678.	1.2	41
58	Evidence Synthesis for Decision Making 1. Medical Decision Making, 2013, 33, 597-606.	1.2	137
59	Evidence Synthesis for Decision Making 3. Medical Decision Making, 2013, 33, 618-640.	1.2	371
60	Selecting the best scale for measuring treatment effect in a network metaâ€analysis: a case study in childhood nocturnal enuresis. Research Synthesis Methods, 2012, 3, 126-141.	4.2	21
61	Consistency and inconsistency in network metaâ€analysis: concepts and models for multiâ€arm studies. Research Synthesis Methods, 2012, 3, 98-110.	4.2	1,283
62	Accounting for correlation in network metaâ€analysis with multiâ€arm trials. Research Synthesis Methods, 2012, 3, 142-160.	4.2	61
63	Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology, 2012, 12, 9.	1.4	1,465
64	Survival Time Outcomes in Randomized, Controlled Trials and Meta-Analyses: The Parallel Universes of Efficacy and Cost-Effectiveness. Value in Health, 2011, 14, 640-646.	0.1	34
65	Linear inference for mixed treatment comparison meta-analysis: A two-stage approach. Research Synthesis Methods, 2011, 2, 43-60.	4.2	72
66	Indirect and mixed treatment comparisons in arthritis research. Rheumatology, 2011, 50, iv5-iv9.	0.9	16
67	Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies. Research Synthesis Methods, 2010, 1, 239-257.	4.2	16
68	Network Meta-Analysis with Competing Risk Outcomes. Value in Health, 2010, 13, 976-983.	0.1	55
69	Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine, 2007, 26, 3681-3699.	0.8	92
70	Assessing Evidence Inconsistency in Mixed Treatment Comparisons. Journal of the American Statistical Association, 2006, 101, 447-459.	1.8	631
71	Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis. Pharmacoeconomics, 2006, 24, 1-19.	1.7	352
72	A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Statistics in Medicine, 2003, 22, 2995-3016.	0.8	109

#	Article	IF	CITATIONS
73	Markov Chain Monte Carlo Estimation of a Multiparameter Decision Model: Consistency of Evidence and the Accurate Assessment of Uncertainty. Medical Decision Making, 2002, 22, 359-371.	1.2	44